Company Information
CIN
Status
Date of Incorporation
13 January 1994
State / ROC
Delhi / ROC Delhi
Last Balance Sheet
31 March 2023
Last Annual Meeting
22 September 2023
Paid Up Capital
44,912,200
Authorised Capital
100,000,000
Directors
Canakapalli Bhaktavatasala Rao
Director/Designated Partner
over 2 years ago
over 2 years ago
Geeta Mathur
Director/Designated Partner
over 2 years ago
over 2 years ago
Deepak Bahri
Director/Designated Partner
over 2 years ago
over 2 years ago
Mahesh Kumar Garg
Director/Designated Partner
over 2 years ago
over 2 years ago
Pratik Nupendrakumar Shah
Director/Designated Partner
over 3 years ago
over 3 years ago
Jagdish Viswanath Dore
Director
over 16 years ago
over 16 years ago
Past Directors
Arvind Sharma
Additional Director
almost 7 years ago
almost 7 years ago
Govind Shanker Pandey
Director
about 9 years ago
about 9 years ago
Mandar Vipin Shah
Additional Director
almost 10 years ago
almost 10 years ago
Rama Kant Sharma
Director
almost 32 years ago
almost 32 years ago
Patents
PLEASE SEE THE ATTACHED SEPECATION
The present invention provides an improved novel process of manufacturing a sterile,
ophthalmic pharmaceutical suspension comprising an active ingredient(s) such as carbonic
anhydrase inhibitors (CAIs) wherein the said process involves solubilization, followed by
controlled precipitation of carbonic anhydrase inh...
PLEASE SEE THE ATTACHED SPECIFICATION.
The present invention provides a stable, aqueous solution comprising a non-steroidal antiinflammatory
drug (NSAID) such as bromfenac or a pharmacologically acceptable salt or a
hydrate thereof and a solubilizer.
The present invention provides methods to reduce the level of degradation of bromfenac
with the addit...
The present invention provides an aqueous ophthalmic composition comprising an alpha-2
adrenergic receptor agonist and a non-ionic cellulosic polymer, the solution having a pH less
than 6.5. The present invention also provides an aqueous ophthalmic composition comprising an
alpha-2 adrenergic receptor agonist and...
The present invention relates to a process for manufacturing an ophthalmic formulation of a carbonic anhydrase inhibitor, hydroxyl ethyl cellulose (HEC), and a beta-adrenergic antagonist for use in the treatment of ocular hypertension and glaucoma wherein the ophthalmic pharmaceutical formulation is devoid of benzal...
The present invention provides a process of manufacturing a sterile, ophthalmic
pharmaceutical suspension comprising sterile active ingredient(s) such as sterile carbonic
anhydrase inhibitors (CAIs) wherein the process does not involve the use of any special
equipment’s such as ball mill, milling bottle and/or je...
The present invention provides an improved novel process of manufacturing a sterile,
ophthalmic pharmaceutical suspension comprising an active ingredient(s) such as carbonic
anhydrase inhibitors (CAIs) wherein the said process involves solubilization, followed by
controlled precipitation of carbonic anhydrase inh...
An aqueous ophthalmic composition, comprising: a therapeutically effective amount of brimonidine or their saltsthereof; a therapeutically effective amount of brinzolamide or their saltsthereof; buffers at a concentration that is at least about 0.05% w/v to 5.0% w/v of the ophthalmic composition; a preservative and; ...
The present invention provides the sterilization of an ophthalmic composition comprising timolol or salt thereof optionally with pharmaceutically acceptable agent(s) wherein the sterilization is achieved through aseptic filtration technique. Further the present invention provides the sterilization process by optimis...
The present invention relates to an ophthalmic pharmaceutical composition comprising a combination of fluoroquinolone antibacterial agent and an anti-inflammatory agent along with a complexing agent and water. The composition is having a pH between 4 and 8. The present invention also relates to the methods of making...
The present invention provides an ophthalmic composition comprising a combination of mydriatic agent and anti-muscarinic agent along with pharmaceutically acceptable excipients, wherein the pH of the composition is in the range of 3.5 to 8.5. The ophthalmic composition of the present invention has synergistic mydria...
Registered Trademarks
[Class : 16] Paper, Cardboard And Goods Made From These Materials; Not Included In Other Classes; Printed Matter (Printing Products); Bookbinding Material; Photographs; Stationery; Adhesive For Stationery Or Household Purposes; Artists” Materials; Paintbrushes; Typewriters And Office Requisites (Except Furniture); Instrumental Or Teaching Material (Except Apparatus); Plastic...
[Class : 44] Medical Services, Veterinary Services, Hygienic And Beauty Care For Human Beings Or Animals; Agriculture, Horticulture, And Forestry Services.
[Class : 10] Surgical, Medical, Dental, And Veterinary Apparatus And Instruments, Artificial Limbs, Eyes, And Teeth; Orthopedic Articles; Suture Materials;
View +114 more Brands for Sentiss Pharma Private Limited.
Charges
16 July 2019
Citi Bank N.a.
25 Crore
03 May 2018
Yes Bank Limited
21 Crore
17 November 2011
Citi Bank N.a.
44 Crore
30 January 2008
3i Infotech Trusteeship Services Limited
41 Crore
18 February 2019
Dbs Bank India Limited
30 Crore
22 December 2009
Icici Bank Limited
15 Crore
14 August 2013
Standard Chartered Bank
21 Crore
16 October 2002
Canara Bank
2 Crore
07 October 2004
Canara Bank
4 Crore
09 June 1995
Canara Bank
14 Crore
26 November 2009
Canara Bank
116 Crore
11 March 2002
Canara Bank
116 Crore
28 September 1999
Canara Bank
1 Crore
23 August 2008
Canara Bank
130 Crore
23 August 2008
Canara Bank
3 Crore
05 March 2008
Canara Bank
58 Crore
03 November 2005
Canara Bank
4 Crore
05 March 2008
Canara Bank
2 Crore
26 November 2009
Canara Bank
14 Crore
03 November 2005
Canara Bank
21 Crore
14 March 2007
Canara Bank
2 Crore
12 May 2006
Icici Bank Limited
14 Crore
14 October 2008
3i Infotech Trusteeship Services Limited
3 Crore
14 June 2007
Icici Bank Limited
1 Crore
12 May 2006
Icici Bank Limited
6 Crore
23 January 2020
Dbs Bank India Limited
30 Crore
23 September 2023
Others
0
23 January 2020
Others
0
03 May 2018
Yes Bank Limited
0
05 March 2008
Canara Bank
0
17 November 2011
Citi Bank N.a.
0
18 February 2019
Others
0
16 July 2019
Citi Bank N.a.
0
03 November 2005
Canara Bank
0
05 March 2008
Canara Bank
0
14 March 2007
Canara Bank
0
12 May 2006
Icici Bank Limited
0
12 May 2006
Icici Bank Limited
0
28 September 1999
Canara Bank
0
09 June 1995
Canara Bank
0
11 March 2002
Canara Bank
0
03 November 2005
Canara Bank
0
14 August 2013
Standard Chartered Bank
0
26 November 2009
Canara Bank
0
23 August 2008
Canara Bank
0
23 August 2008
Canara Bank
0
22 December 2009
Icici Bank Limited
0
16 October 2002
Canara Bank
0
26 November 2009
Canara Bank
0
14 October 2008
3i Infotech Trusteeship Services Limited
0
07 October 2004
Canara Bank
0
14 June 2007
Icici Bank Limited
0
30 January 2008
3i Infotech Trusteeship Services Limited
0
23 September 2023
Others
0
23 January 2020
Others
0
03 May 2018
Yes Bank Limited
0
05 March 2008
Canara Bank
0
17 November 2011
Citi Bank N.a.
0
18 February 2019
Others
0
16 July 2019
Citi Bank N.a.
0
03 November 2005
Canara Bank
0
05 March 2008
Canara Bank
0
14 March 2007
Canara Bank
0
12 May 2006
Icici Bank Limited
0
12 May 2006
Icici Bank Limited
0
28 September 1999
Canara Bank
0
09 June 1995
Canara Bank
0
11 March 2002
Canara Bank
0
03 November 2005
Canara Bank
0
14 August 2013
Standard Chartered Bank
0
26 November 2009
Canara Bank
0
23 August 2008
Canara Bank
0
23 August 2008
Canara Bank
0
22 December 2009
Icici Bank Limited
0
16 October 2002
Canara Bank
0
26 November 2009
Canara Bank
0
14 October 2008
3i Infotech Trusteeship Services Limited
0
07 October 2004
Canara Bank
0
14 June 2007
Icici Bank Limited
0
30 January 2008
3i Infotech Trusteeship Services Limited
0
